Thus, HSCs are the main effector cells for the pro-fibrotic function of Ccne1, but presumably only one out of several effector cells for the oncogenic function of Ccne1. Nevertheless, our data strongly indicate that therapeutic Ccne1 inhibition will be beneficial for the treatment of both liver fibrosis and fibrosis-induced HCC. This evidence concerns the gene CCNE1 and hepatocellular carcinoma.